



Plenary sitting

B8-0358/2018

4.9.2018

MOTION FOR A RESOLUTION

pursuant to Rule 133 of the Rules of Procedure
on CAR-T tumour cell therapy

Nicola Caputo

Motion for a European Parliament resolution on CAR-T tumour cell therapy

The European Parliament,

- having regard to Rule 133 of its Rules of Procedure,
- A. whereas the first CAR therapy for treating diffuse large B-cell lymphoma in adults and acute lymphoblastic leukaemia in children and young people has received community approval;
- B. whereas the drug agencies in individual countries need to reduce the cost of the therapy and identify clinics where it can be carried out, potentially leading to a very long waiting period;
- C. whereas, to select these clinics, it will be necessary to establish a set of requirements and features with which the authorised clinics must comply, and that during the waiting period, pharmaceutical companies producing the treatment will administer it to a limited group of volunteers;
- D. whereas the potential side effects of the therapy may be serious, and studies into treatments to eliminate them are already in progress;
 1. Calls on the Commission to create a research and testing hub for cancer cell therapies similar to CAR-T and for treatments able to eliminate their potential side effects;
 2. Calls on the Commission to set up public clinics authorised to administer such treatments during the negotiation period and to work to implement clear deadlines on the waiting time between the approval of a treatment and its commercialisation.